Rosiglitazone and cardiovascular risk
- Sanjay KaulAffiliated withDivision of Cardiology, Cedars-Sinai Medical Center Email author
- , George A. Diamond
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
A meta-analysis of 42 clinical trials suggested that rosiglitazone, a widely used thiazolidinedione, was associated with a 43% greater risk of myocardial infarction (P = 0.03) and a 64% greater risk of cardiovascular death (P = 0.06). However, a number of criticisms have been raised that potentially undermine the conclusions of this analysis. In this article, we point out some of these limitations, summarize the currently available evidence concerning rosiglitazone and cardiovascular risk, share implications for drug safety evaluation, and offer practical recommendations to health care providers. We conclude that the data showing the increased risk for myocardial infarction and death from cardiovascular disease for diabetic patients taking rosiglitazone are inconclusive.
- Rosiglitazone and cardiovascular risk
Current Atherosclerosis Reports
Volume 10, Issue 5 , pp 398-404
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Industry Sectors